Investment
Features
FeesSafety
Academy
More
Pluang+

Compare AMETEK, Inc. (AME) vs Alexandria Real Estate Equities Inc (ARE) Price & Performance

AMETEK, Inc.Trade
Alexandria Real Estate Equities IncTrade

Price performance (Past 24H)

Key statistics

AMETEK, Inc. vs Alexandria Real Estate Equities Inc — how do they compare? AMETEK, Inc. trades at $255.78 (market cap $57.98B), while Alexandria Real Estate Equities Inc trades at $48.5 (market cap $8.32B). The key difference: AMETEK, Inc. is far larger — about 7× Alexandria Real Estate Equities Inc's market cap, and Alexandria Real Estate Equities Inc pays the higher dividend (5.96%). Which is the better fit depends on your goals.

AMEARE
Market Cap
$57.98B$8.32B
Sector
IndustrialsReal Estate
52-Week High
$256.30$87.45
52-Week Low
$179.28$40.41
Enterprise Value
$59.52B$21.02B
Dividend Yield
0.54%5.96%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

AMETEK, Inc.

AME trades at $253.66, up 0.91% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats (Q2 2026 EPS of $2.09 vs. $1.99 expected), revenue growth to $7.40B in 2025, and robust profitability (20.04% net margin). Recent news highlights momentum in 3D printing and electronics testing sectors. Analyst consensus is strongly bullish with a $281.86 price target.

Outlook remains positive given earnings momentum and raised guidance, but risks include elevated valuation (P/E 37.08) and RSI overbought signals. Institutional support is strong with no sell ratings. The stock offers growth potential but requires monitoring of valuation metrics amid current levels near resistance.

Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities (ARE) trades at $49.74, up 2.6% on the day, yet technical indicators signal a bearish trend with support near $47. The stock shows mixed fundamentals: a high P/E of 102.99 and negative net income margin of -37.12% contrast with strong FFO beats and a dividend payout. Recent Q2 2026 earnings missed on EPS but beat on FFO, with leasing momentum improving. Analyst consensus is a 'Hold' with a $53.71 price target, indicating modest upside potential amid operational challenges.

Outlook remains cautious due to persistent net losses and high debt, though leasing recovery and institutional interest offer hope. Risks include occupancy pressures and macroeconomic headwinds, but the current discount to book value (P/B 0.55) may attract value investors if operational trends stabilize.

Returns comparison

Trailing returns across standard periods

About AMETEK, Inc.

Ametek is a diversified industrial conglomerate with over $6 billion in sales. The firm operates through an electronic instruments group and an electromechanical group. EIG designs and manufactures differentiated and advanced instruments for the process, aerospace, power, and industrial end markets. EMG is a focused, niche supplier of highly engineered automation solutions, thermal management systems, specialty metals, and electrical interconnects, among other products. About half of the firm's sales are made in the United States. The firm's asset-light strategy in place for nearly two decades emphasizes growth through acquisitions, new product development through research and development, driving operational efficiencies, and global and market expansion.

Read more on AME

About Alexandria Real Estate Equities Inc

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a significant market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle. Alexandria has a longstanding and proven track record of developing Class A properties clustered in urban life science, agtech, and technology campuses that provide tenants with highly dynamic and collaborative environments. Alexandria also provides strategic capital to transformative life science, agtech, and technology companies through venture capital platform.

Read more on ARE